Liposomal Amphotericin B
スポンサーリンク
概要
- 論文の詳細を見る
Liposomal amphotericin B (AmBisome™) is a DDS (drug delivery system) formulation of amphotericin B (AMPH-B), and has been developed in an attempt to reduce the toxicity of AMPH-B while retaining its therapeutic efficacy. AMPH-B has been the "gold standard" of antifungal therapy over the past four decades. It has a broad spectrum of fungicidal activity against a number of clinically important pathogens including Aspergillus and Candida. The mechanism of action of AMPH-B involves binding to ergosterol, the principal sterol in fungal cell membranes. Binding to ergosterol causes an increase in fungal membrane permeability, electrolyte leakage, and cell death. AMPH-B has affinity for cholesterol in mammalian membranes, which leads to severe side-effects including kidney damage.AmBisome is a unilamellar vesicle composed of AMPH-B and phospholipid. Upon administration, AmBisome remains intact in the blood and distributes to the tissues where fungal infection may occur, and is disrupted after attachment to the outside of fungal cells, resulting in fungal cell death.AmBisome and AMPH-B show similar in vitro and in vivo antifungal activity and clinical efficacy. However, AmBisome has less infusion-related toxicity and nephrotoxicity than AMPH-B.
- 日本医真菌学会の論文
日本医真菌学会 | 論文
- (1→3)-β-D-グルカン測定の問題点と進歩
- 両側の肺空洞病変にアスペルギルス感染を合併し抗真菌薬, ミカファンギンとイトラコナゾールの併用療法が有効であった Wegener 肉芽腫症の一例
- Trichophyton tonsurans 臨床分離株に対する各種抗真菌薬の in vitro 抗真菌活性
- 爪白癬の治療について : 日本医真菌学会標準化委員会提案2007
- Candida 属菌種のアゾール系薬感受性試験における現行の日本医真菌学会法, およびその改変法とNCCLS M27-A2法との相関性に関する検討